异动解读｜药捷安康-B盘中上涨6.19%，生物科技板块集体走强叠加近期多项临床进展催化

行情直击07-06

7月6日，药捷安康-B盘中上涨6.19%，报12.52港元，成交额1.23亿港元。

消息面上，公司近期研发进展密集释放：7月1日公告核心产品替恩戈替尼单药治疗晚期胆管癌的全球多中心注册性III期临床试验已完成入组，标志着该品种向注册上市迈出关键一步；同日TT-01488片联合抗CD20单抗治疗套细胞淋巴瘤的II期临床获国家药监局批准开展。此外，公司6月28日宣布拟回购最多1亿元H股，提振市场信心。板块层面，生物科技股今日集体走强，信达生物涨7.29%、科伦博泰生物涨6.21%、荣昌生物涨6.21%，行业情绪共振推动个股反弹。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1198637861?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-06 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198637861","market":"us","top_or_hot":-1,"title":"异动解读｜药捷安康-B盘中上涨6.19%，生物科技板块集体走强叠加近期多项临床进展催化","media":"行情直击","content":"<p><p>7月6日，药捷安康-B盘中上涨6.19%，报12.52港元，成交额1.23亿港元。</p><p>消息面上，公司近期研发进展密集释放：7月1日公告核心产品替恩戈替尼单药治疗晚期胆管癌的全球多中心注册性III期临床试验已完成入组，标志着该品种向注册上市迈出关键一步；同日TT-01488片联合抗CD20单抗治疗套细胞淋巴瘤的II期临床获国家药监局批准开展。此外，公司6月28日宣布拟回购最多1亿元H股，提振市场信心。板块层面，生物科技股今日集体走强，信达生物涨7.29%、科伦博泰生物涨6.21%、荣昌生物涨6.21%，行业情绪共振推动个股反弹。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜药捷安康-B盘中上涨6.19%，生物科技板块集体走强叠加近期多项临床进展催化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜药捷安康-B盘中上涨6.19%，生物科技板块集体走强叠加近期多项临床进展催化\n</h2>\n\n<h4 class=\"meta\">\n\n2026-07-06 10:30 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月6日，药捷安康-B盘中上涨6.19%，报12.52港元，成交额1.23亿港元。消息面上，公司近期研发进展密集释放：7月1日公告核心产品替恩戈替尼单药治疗晚期胆管癌的全球多中心注册性III期临床试验已完成入组，标志着该品种向注册上市迈出关键一步；同日TT-01488片联合抗CD20单抗治疗套细胞淋巴瘤的II期临床获国家药监局批准开展。此外，公司6月28日宣布拟回购最多1亿元H股，提振市场信心。...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1198637861","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198637861","pubTimestamp":1783305010,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"7月6日，药捷安康-B盘中上涨6.19%，报12.52港元，成交额1.23亿港元。此外，公司6月28日宣布拟回购最多1亿元H股，提振市场信心。板块层面，生物科技股今日集体走强，信达生物涨7.29%、科伦博泰生物涨6.21%、荣昌生物涨6.21%，行业情绪共振推动个股反弹。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"Interpretation of the change | Yaojie Ankang-B rose by 6.19% in the intraday session, and the collective strength of the biotechnology sector was superimposed on the catalysis of many recent clinical progress","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"7月6日，药捷安康-B盘中上涨6.19%，报12.52港元，成交额1.23亿港元。消息面上，公司近期研发进展密集释放：7月1日公告核心产品替恩戈替尼单药治疗晚期胆管癌的全球多中心注册性III期临床试验已完成入组，标志着该品种向注册上市迈出关键一步；同日TT-01488片联合抗CD20单抗治疗套细胞淋巴瘤的II期临床获国家药监局批准开展。此外，公司6月28日宣布拟回购最多1亿元H股，提振市场信心。板块层面，生物科技股今日集体走强，信达生物涨7.29%、科伦博泰生物涨6.21%、荣昌生物涨6.21%，行业情绪共振推动个股反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198637861","isCrawlerRequest":true}